Article
Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2017
Tokaca Nadza, Wotherspoon Andrew, Nicholson Andrew G, Fotiadis Nicos, Thompson Lisa, Popat Sanjay
Abstract excerpt
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.